{"entity":{"id":"paq-therapeutics","kind":"company","name":"PAQ Therapeutics","aka":[],"tldr":"PAQ Therapeutics makes medicines that get the cell to destroy the faulty KRAS protein that drives many bowel, pancreatic and lung cancers, rather than simply blocking it.","summary":"PAQ Therapeutics, Inc., based in Burlington, Massachusetts, develops targeted protein degraders against KRAS. PT0253 is in a phase 1 trial, alone and with chemotherapy, in advanced solid tumours with the KRAS G12D mutation (NCT06797336). PT0511, which the company describes as a pan-KRAS degrader, entered a phase 1 trial in KRAS-mutated or amplified solid tumours, with the first patient dosed by January 2026 (NCT07300150). The company announced a USD 39 million Series B in May 2025 and an extension in January 2026 bringing total Series B financing to USD 77 million. Its first registered cancer trial, NCT06797336, was posted on ClinicalTrials.gov in January 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.paqtx.com/"},{"label":"Series B release, May 2025","url":"https://www.paqtx.com/news/paq-therapeutics-announces-39-million-series-b-financing-and-initiates-phase-1-trial-to-advance-novel-approach-addressing-kras-driven-cancers-with-high-unmet-need/"},{"label":"ClinicalTrials.gov: phase 1 trial of PT0253 (NCT06797336)","url":"https://clinicaltrials.gov/study/NCT06797336"},{"label":"ClinicalTrials.gov: phase 1 trial of PT0511 (NCT07300150)","url":"https://clinicaltrials.gov/study/NCT07300150"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["protac-degrader","kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website read on 29 October 2026 through a summarising fetch, with the release titles and amounts checked against the release URLs. Founding year not stated on the company website. Investor logos on the site include Lilly Asia Ventures and Matrix Partners China, but no release read ties them to a round, so no investors are recorded. Trial facts from ClinicalTrials.gov records read on 29 October 2026."],"hq":"Burlington, MA","country":"US","companyType":"biotech","website":"https://www.paqtx.com/","stage":"growth","investors":[],"funding":[{"round":"Series B","year":2025,"amountUsd":39000000,"source":"https://www.paqtx.com/news/paq-therapeutics-announces-39-million-series-b-financing-and-initiates-phase-1-trial-to-advance-novel-approach-addressing-kras-driven-cancers-with-high-unmet-need/"},{"round":"Series B extension","year":2026,"amountUsd":38000000,"source":"https://www.paqtx.com/news/paq-therapeutics-announces-series-b-extension-bringing-total-series-b-financing-to-77-million-first-patient-dosed-in-phase-1-trial-of-pt0511-a-pan-kras-degrader/","note":"The release gives a total Series B of USD 77 million; the extension amount is the difference from the USD 39 million first close"}]},"route":"/companies/paq-therapeutics/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}]}}